期刊文献+

自体造血干细胞移植治疗老年人恶性血液病临床观察 被引量:6

原文传递
导出
摘要 由于人口老龄化,老年人恶性血液病发病率呈上升趋势。老年患者通常对常规化疗反应差,严重影响了老年患者的缓解率及长期生存率。近年来,由于造血干细胞移植(HSCT)技术的不断改进和完善及支持治疗的进步,国外已将HSCT的年龄上限提升至60~65岁,而国内通常年龄限定在55岁左右。我院1998年1月至2008年1月对老年人恶性血液病患者进行自体HSCT,获得较好疗效,现报道如下。
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2010年第3期235-236,共2页 Chinese Journal of Geriatrics
  • 相关文献

参考文献3

  • 1Olivieri A,Bruno M,Brunori A,et al.Early and late non relapse mortality in 2500 adults receiving AST for AML:a gitmo survey.Bone Marrow Transplantation,2007,39:146.
  • 2Badros A,Barlogie B,Siegel E,et al.Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years.Br J Haematol,2001,114:600-607.
  • 3Gopal AK,Gooley TA,Golden JB,et al.Efficacy of high-dose therapy and autologous hematopoietic stern cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.Bone Marrow Transplant,2001,27:593-599.

同被引文献64

  • 1苗瑞新.造血干/祖细胞动员临床研究新进展[J].国际移植与血液净化杂志,2006,4(3):32-35. 被引量:2
  • 2粟小莲.老年恶性血液病合并感染临床分析[J].临床医学,2006,26(12):36-36. 被引量:2
  • 3王华,吴巨峰,姚红霞.恶性血液病并医院感染性败血症临床分析[J].实用医学杂志,2007,23(17):2718-2719. 被引量:6
  • 4Cavo M,Rajkumar SV,Palumbo A. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem celltransplantation[J].{H}Blood,2011,(23):6063-6073.
  • 5Koreth J,Cutler CS,Djulbegovic B. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma:A systematic review and meta-analysis of randomized control ed trials[J].{H}Biology of Blood and Marrow Transplantation,2007,(02):183-196.
  • 6Lentzsch S,O'Sul ivan A,Kennedy RC. Combination of bendamustine,lenalidomide,and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective:results of phase 1/2 open-label,dose escalation study[J].{H}Blood,2012,(20):4608-4613.
  • 7Eom HS,Min CK,Cho BS. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem celltransplantation for multiple myeloma[J].{H}Japanese Journal of Clinical Oncology,2009,(07):449-455.
  • 8Rosi?ol L,Oriol A,Teruel AI. Superiority of bortezomib,thalidomide,and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma:a randomized phase 3 PETHEMA/GEM study[J].{H}Blood,2012,(08):1589-1596.
  • 9Mikhael JR,Reeder CB,Libby III EN. Results From the Phase II Dose Expansion of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone(CYCLONE)in Patients with Newly Diagnosed Multiple Myeloma[J].Blood(ASH Annual Meeting Abstracts),2012.445.
  • 10Roussel M,Moreau P,Huynh A. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem celltransplantation in patients with de novo multiple myeloma:a phase 2 study of the Intergroupe Francophone du Myelome (IFM)[J].{H}Blood,2010,(01):32-37.

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部